Structure-Activity Relationship Studies on Clinically Relevant HIV-1 NNRTIs

Author(s): R.K. Rawal, V. Murugesan, S.B. Katti

Journal Name: Current Medicinal Chemistry

Volume 19 , Issue 31 , 2012

Become EABM
Become Reviewer
Call for Editor


In addition to the nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs) and integrase inhibitors (INIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs) have contributed significantly in the treatment of HIV-1 infections. More than 60 structurally different classes of compounds have been identified as NNRTIs, which are specifically inhibiting HIV-1 reverse transcriptase (RT). Five NNRTIs (nevirapine, delavirdine, efavirenz, etravirine and rilpivirine) have been approved by US Food and Drug Administration (FDA) for clinical use. The NNRTIs bind with a specific ‘pocket’ site of HIV-1 RT (allosteric site) that is closely associated with the NRTI binding site. Due to mutations of the amino acid residues surrounding the NNRTI-binding site, NNRTIs are notorious for rapidly eliciting resistance. Though, the emergence of resistant HIV strains can be circumvented if the NNRTIs are used either alone or in combination with NRTIs (AZT, 3TC, ddI, ddC, TVD or d4T) and PIs (Indinavir, nelfinavir, saquinavir, ritonavir and lopinavir etc.) as shown by both a decrease in plasma HIV-1 RNA levels and increased CD4 T-cells. Here we are going to discuss recent advances in structure activity relationship studies on nevirapine, delavirdine, efavirenz, etravirine, rilpivirine and 4-thiazolidinones (privileged scaffold) HIV-1 NNRTIs.

Keywords: AIDS, delavirdine, DNA, efavirenz, etravirine, HIV, nevirapine, NNRTIs, NRTIs, PIs, rilpivirine, RNA

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 31 October, 2012
Page: [5364 - 5380]
Pages: 17
DOI: 10.2174/092986712803833326
Price: $65

Article Metrics

PDF: 46